Binding affinity and agonist activity of putative endogenous cannabinoids at the human neocortical CB1 receptor

Biochemical Pharmacology

Volumn 69, Issue 1, 2005, Pages 169-178

  Steffens, Marc ^a   Zentner, Josef ^b   Honegger, Jürgen ^b   Feuerstein, Thomas J ^a  

^a Breisacherstrasse 64 D 79106 F ^*  (Germany)

^b Neurochirurgische Univ Klin   (Germany)

Author keywords

2 Arachidonylglycerol; Anandamide; Endocannabinoid; Human brain; Noladin ether; Virodhamine

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 ARACHIDONOYLGLYCEROL; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CYCLIC AMP; FORSKOLIN; NOLADIN ETHER; PROTEINASE INHIBITOR; TRITIUM; UNCLASSIFIED DRUG; VIRODHAMINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG EFFECT; ENZYME STABILITY; FEMALE; HUMAN; HUMAN TISSUE; MALE; NEOCORTEX; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY;

ADOLESCENT; ADULT; ANIMALS; BINDING SITES; CHILD; CHILD, PRESCHOOL; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCANNABINOIDS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOCORTEX; PROTEIN BINDING; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1;

EID: 9944235039     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2004.08.033     Document Type: Article

References (44)

1. W.A. Devane, L. Hanus, A. Breuer, R.G. Pertwee, L.A. Stevenson, and G. Griffin Isolation and structure of a brain constituent that binds to the cannabinoid receptor Science 258 1992 1946 1949
2. T. Sugiura, S. Kondo, A. Sukagawa, S. Nakane, A. Shinoda, and K. Itoh 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain Biochem Biophys Res Commun 215 1995 89 97
3. V. Di Marzo, D. Melck, T. Bisogno, and L. De Petrocellis Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action Trends Neurosci 21 1998 521 528
4. V. Di Marzo, A. Fontana, H. Cadas, S. Schinelli, G. Cimino, and J.C. Schwartz Formation and inactivation of endogenous cannabinoid anandamide in central neurons Nature 372 1994 686 691
5. N. Stella, P. Schweitzer, and D. Piomelli A second endogenous cannabinoid that modulates long-term potentiation Nature 388 1997 773 778
6. A. Giuffrida, M. Beltramo, and D. Piomelli Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology J Pharmacol Exp Ther 298 2001 7 14
7. B.F. Cravatt, D.K. Giang, S.P. Mayfield, D.L. Boger, R.A. Lerner, and N.B. Gilula Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides Nature 384 1996 83 87
8. B.F. Cravatt, K. Demarest, M.P. Patricelli, M.H. Bracey, D.K. Giang, and B.R. Martin Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase Proc Natl Acad Sci 98 2001 9371 9376
9. S.K. Goparaju, N. Ueda, H. Yamaguchi, and S. Yamamoto Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand FEBS Lett 422 1998 69 73
10. V. Di Marzo, T. Bisogno, T. Sugiura, D. Melck, and L. De Petrocellis The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide Biochem J 331 1998 15 19
11. T.P. Dinh, D. Carpenter, F.M. Leslie, T.F. Freund, I. Katona, and S.L. Sensi Brain monoglyceride lipase participating in endocannabinoid inactivation Proc Natl Acad Sci 99 2002 10819 10824
12. S.M. Saario, J.R. Savinainen, J.T. Laitinen, T. Jarvinen, and R. Niemi Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes Biochem Pharmacol 67 2004 1381 1387
13. J. Romero, C.J. Hillard, M. Calero, and A. Rabano Fatty acid amide hydrolase localization in the human central nervous system: an immunohistochemical study Brain Res Mol Brain Res 100 2002 85 93
14. T.F. Freund, I. Katona, and D. Piomelli Role of endogenous cannabinoids in synaptic signaling Physiol Rev 83 2003 1017 1066
15. C.J. Hillard, W.S. Edgemond, and W.B. Campbell Characterization of ligand binding to the cannabinoid receptor of rat brain membranes using a novel method: application to anandamide J Neurochem 64 1995 677 683
16. 1 receptor-dependent G-protein activation in rat cerebellar membranes Br J Pharmacol 134 2001 664 672
17. 1 receptor-mediated modulation of evoked dopamine release and of adenylyl cyclase activity in the human neocortex Br J Pharmacol 141 2004 1193 1203
18. C.J. Hillard Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol Prostaglandins Other Lipid Mediat 61 2000 3 18
19. T. Bisogno, F. Berrendero, G. Ambrosino, M. Cebeira, J.A. Ramos, and J.J. Fernandez-Ruiz Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function Biochem Biophys Res Commun 256 1999 377 380
20. 1 receptor is a 2- arachidonoylglycerol receptor. Structure-activity relationship of 2-arachidonoylglycerol, ether-linked analogues, and related compounds J Biol Chem 274 1999 2794 2801
21. T. Sugiura, and K. Waku 2-Arachidonoylglycerol and the cannabinoid receptors Chem Phys Lipids 108 2000 89 106
22. 1 receptor Proc Natl Acad Sci 98 2001 3662 3665
23. 1 receptor J Pharmacol Exp Ther 301 2002 1020 1024
24. F. Fezza, T. Bisogno, A. Minassi, G. Appendino, R. Mechoulam, and V. Di Marzo Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues FEBS Lett 513 2002 294 298
25. W.A. Devane, F.A. Dysarz 3rd, M.R. Johnson, L.S. Melvin, and A.C. Howlett Determination and characterization of a cannabinoid receptor in rat brain Mol Pharmacol 34 1988 605 613
26. M. Steffens, T.J. Feuerstein, V. van Velthoven, P. Schnierle, and R. Knörle Quantitative measurement of depolarization-induced anandamide release in human and rat neocortex Naunyn-Schmiedeberg's Arch Pharmacol 368 2003 432 436
27. O.H. Lowry, N.J. Rosebrough, A.L. Farr, and R.J. Randall Protein measurement with the Folin phenol reagent J Biol Chem 193 1951 265 275
28. T.J. Feuerstein, and N. Limberger Mathematical analysis of the control of neurotransmitter release by presynaptic receptors as a supplement to experimental data Naunyn Schmiedebergs Arch Pharmacol 359 1999 345 359
29. H.H. Hansen, P.C. Schmid, P. Bittigau, I. Lastres-Becker, F. Berrendero, and J. Manzanares Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration J Neurochem 78 2001 1415 1427
30. S.O. Jacobsson, T. Wallin, and C.J. Fowler Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors J Pharmacol Exp Ther 299 2001 951 959
31. M. Bidaut-Russell, W.A. Devane, and A.C. Howlett Cannabinoid receptors and modulation of cyclic AMP accumulation in the rat brain J Neurochem 55 1990 21 26
32. S. Mato, A. Pazos, and E.M. Valdizan Cannabinoid receptor antagonism and inverse agonism in response to SR141716A on cAMP production in human and rat brain Eur J Pharmacol 443 2002 43 46
33. R. Mechoulam, S. Ben-Shabat, L. Hanus, M. Ligumsky, N.E. Kaminski, and A.R. Schatz Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors Biochem Pharmacol 50 1995 83 90
34. A.C. Howlett, F. Barth, T.I. Bonner, G. Cabral, P. Casellas, and W.A. Devane International Union of Pharmacology. XXVII. Classification of cannabinoid receptors Pharmacol Rev 54 2002 161 202
35. N. Nagan, and R.A. Zoeller Plasmalogens: biosynthesis and functions Prog Lipid Res 40 2001 199 229
36. S. Oka, A. Tsuchie, A. Tokumura, M. Muramatsu, Y. Suhara, and H. Takayama Ether-linked analogue of 2-arachidonoylglycerol (noladin ether) was not detected in the brains of various mammalian species J Neurochem 85 2003 1374 1381
37. M.P. Patricelli, and B.F. Cravatt Fatty acid amide hydrolase competitively degrades bioactive amides and esters through a nonconventional catalytic mechanism Biochemistry 38 1999 14125 14130
38. C.C. Felder, A. Nielsen, E.M. Briley, M. Palkovits, J. Priller, and J. Axelrod Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat FEBS Lett 393 1996 231 235
39. Y.P. Maneuf, and J.M. Brotchie Paradoxical action of the cannabinoid WIN 55,212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices 120 1997 1397 1398
40. D.W. Bonhaus, L.K. Chang, J. Kwan, and G.R. Martin Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses J Pharmacol Exp Ther 287 1998 884 888
41. A. Baba, T. Tatsuno, and H. Iwata Modulation by unsaturated fatty acids of norepinephrine- and adenosine-induced formation of cyclic AMP in brain slices J Neurochem 42 1984 192 197
42. 2+ mobilization, cyclic AMP levels and membrane fluidity Biochim Biophys Acta 1054 1990 114 118
43. L.J. Sim-Selley, L.K. Brunk, and D.E. Selley Inhibitory effects of SR141716 on G-protein activation in rat brain Eur J Phrmacol 414 2001 135 143
44. J.P. Meschler, D.M. Kraichely, G.H. Wilken, and A.C. Howlett Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H- pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4- methoxyphenyl)-1H-pyrazole-3-carboxylic acid phenylamide (CP-27281) for the CB(1) cannabinoid receptor Biochem Pharmacol 60 2000 1315 1323